



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	96700/1165
-------	---	----	---	------------------------	------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	^{T²}
	1	Jirousek, M. et al. "(S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase C β " J. Med. Chem. 39(14):2664-2671 (1996).	
	2	O'Brian, C.A. and Ward, N.E. "ATP-sensitive binding of melittin to the catalytic domain of protein kinase C" Molecular Pharmacology 36(3):355-359 (1989).	
	3	Martiny-Baron, G. et al. "Selective Inhibition of Protein Kinase C Isozymes by the Indolocarbazole Gö 6976" Journal of Biological Chemistry 268(13):9194-9197 (1993).	
	4	Eichholtz, T. et al. "A Myristoylated Pseudosubstrate Peptide, a Novel Protein Kinase C Inhibitor" Journal of Biological Chemistry 268(3):1982-1986 (1993).	
	5	Hofmann, J. "The potential for isoenzyme-selective modulation of protein kinase C" FASEB J. 11:649-669 (1997).	
	6	Mackay, H.J. and Twelves, C.J. "Protein kinase C: a target for anticancer drugs?" J. Endocr. Relat. Cancer 10:389-396 (2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.